NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Perkins Capital Management Inc.

Perkins Capital Management Inc. trimmed its position in NeoGenomics, Inc. (NASDAQ:NEO) by 1.0% in the fourth quarter, Holdings Channel reports. The firm owned 178,950 shares of the medical research company’s stock after selling 1,850 shares during the quarter. NeoGenomics accounts for 2.6% of Perkins Capital Management Inc.’s holdings, making the stock its 10th biggest holding. Perkins Capital Management Inc.’s holdings in NeoGenomics were worth $2,949,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in NeoGenomics in the fourth quarter worth about $26,000. Versant Capital Management Inc grew its stake in NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP acquired a new position in NeoGenomics in the third quarter worth about $40,000. KBC Group NV boosted its stake in NeoGenomics by 33.1% in the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,127 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in NeoGenomics by 203.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 2,787 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

NeoGenomics Stock Performance

NEO opened at $9.86 on Monday. The stock has a market cap of $1.27 billion, a PE ratio of -15.90 and a beta of 1.28. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a twelve month low of $8.98 and a twelve month high of $19.12. The business’s 50 day moving average is $12.34 and its 200-day moving average is $14.56.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. On average, analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on NEO shares. Jefferies Financial Group started coverage on NeoGenomics in a research note on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price for the company. The Goldman Sachs Group decreased their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Needham & Company LLC decreased their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Wednesday, February 19th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Finally, Piper Sandler decreased their target price on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.